,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Apr 2021', 'fs': 'Apr 2021', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Wfo1d2AB'}, 'Id': 'a0POZ00000Wfo1d2AB', 'Event_Date__c': '2021-04-23', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Apr 2021', 'Status_History__c': 'a132P000000DZBtQAO'}, 'change': None}]",Apr 2021,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2021', 'fs': 'Aug 2021', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Wfo1e2AB'}, 'Id': 'a0POZ00000Wfo1e2AB', 'Event_Date__c': '2021-08-02', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Aug 2021', 'Status_History__c': 'a132P000000DZZCQA4'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2021', 'fs': 'Sep 2021', 'change': None}, 'Event_Description': {'s': 'Assigned to Cancer Treatments Advisory Committee meeting to provide advice on Thursday 4 November 2021', 'fs': 'Assigned to Cancer Treatments Advisory Committee meeting to provide advice on Thursday 4 November 2021', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Wfo1f2AB'}, 'Id': 'a0POZ00000Wfo1f2AB', 'Event_Date__c': '2021-09-01', 'Event_Description__c': 'Assigned to Cancer Treatments Advisory Committee meeting to provide advice on Thursday 4 November 2021', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Sep 2021', 'Status_History__c': 'a132P000000DaRMQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p>1.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that daratumumab for the third-line treatment of relapsed or refractory multiple myeloma be listed with a <b>medium</b> <b>priority</b>, in the context of treatment of malignancy, subject to the following Special Authority criteria:</p><p class=""ql-indent-1""><b style=""font-size: 9pt; color: rgb(34, 34, 34);"">DARATUMUMAB</b></p><p class=""ql-indent-1""><b style=""font-size: 9pt; color: rgb(34, 34, 34);"">Initial application</b><span style=""font-size: 9pt; color: rgb(34, 34, 34);""> – (relapsed/refractory multiple myeloma) only from a haematologist or medical practitioner on the recommendation of a haematologist. Approvals valid for 12 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">All of the following:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">1.</span><span style=""font-size: 7pt; color: rgb(34, 34, 34);"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">Patient has relapsed or refractory multiple myeloma with progressive disease; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">2.</span><span style=""font-size: 7pt; color: rgb(34, 34, 34);"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">Patient has received two prior lines of treatment; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">3.</span><span style=""font-size: 7pt; color: rgb(34, 34, 34);"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">Either</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">3.1.</span><span style=""font-size: 7pt; color: rgb(34, 34, 34);"">\xa0\xa0</span><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">Both:</span></p><p class=""ql-indent-3""><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">3.1.1.</span><span style=""font-size: 7pt; color: rgb(34, 34, 34);"">\xa0</span><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">In patients who received first-line bortezomib, patient’s disease was not refractory to bortezomib (ie received &gt;6 months response to first-line bortezomib), nor were they intolerant to bortezomib; and</span></p><p class=""ql-indent-3""><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">3.1.2.</span><span style=""font-size: 7pt; color: rgb(34, 34, 34);"">\xa0</span><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">Daratumumab to be administered in combination with bortezomib and dexamethasone for weeks 1 through 24 and as a monotherapy from week 25 until disease progression; or</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">3.2.</span><span style=""font-size: 7pt; color: rgb(34, 34, 34);"">\xa0\xa0</span><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">Both:</span></p><p class=""ql-indent-3""><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">3.2.1.</span><span style=""font-size: 7pt; color: rgb(34, 34, 34);"">\xa0</span><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">In patients who received first-line bortezomib, patient’s disease was refractory to bortezomib in first line or they were intolerant to bortezomib; and</span></p><p class=""ql-indent-3""><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">3.2.2.</span><span style=""font-size: 7pt; color: rgb(34, 34, 34);"">\xa0</span><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">Daratumumab to be administered in combination with dexamethasone</span></p><p><b style=""font-size: 9pt; color: rgb(34, 34, 34);"">\xa0</b></p><p class=""ql-indent-1""><b style=""font-size: 9pt; color: rgb(34, 34, 34);"">Renewal</b><span style=""font-size: 9pt; color: rgb(34, 34, 34);""> - (relapsed/refractory multiple myeloma) only from a haematologist or any other medical practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">Both:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">1.</span><span style=""font-size: 7pt; color: rgb(34, 34, 34);"">\xa0\xa0</span><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">No evidence of disease progression; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">2.</span><span style=""font-size: 7pt; color: rgb(34, 34, 34);"">\xa0\xa0</span><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">The treatment remains appropriate and patient is benefitting from treatment.</span></p><p class=""ql-indent-1""><br></p><p>1.4<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee requested that its preferences for treatment of patients with multiple myeloma be reviewed should there be a change in the funding landscape regarding the first and/or second line treatment of multiple myeloma.</p>', 'fs': '<p>1.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that daratumumab for the third-line treatment of relapsed or refractory multiple myeloma be listed with a <b>medium</b> <b>priority</b>, in the context of treatment of malignancy, subject to the following Special Authority criteria:</p><p class=""ql-indent-1""><b style=""font-size: 9pt; color: rgb(34, 34, 34);"">DARATUMUMAB</b></p><p class=""ql-indent-1""><b style=""font-size: 9pt; color: rgb(34, 34, 34);"">Initial application</b><span style=""font-size: 9pt; color: rgb(34, 34, 34);""> – (relapsed/refractory multiple myeloma) only from a haematologist or medical practitioner on the recommendation of a haematologist. Approvals valid for 12 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">All of the following:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">1.</span><span style=""font-size: 7pt; color: rgb(34, 34, 34);"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">Patient has relapsed or refractory multiple myeloma with progressive disease; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">2.</span><span style=""font-size: 7pt; color: rgb(34, 34, 34);"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">Patient has received two prior lines of treatment; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">3.</span><span style=""font-size: 7pt; color: rgb(34, 34, 34);"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">Either</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">3.1.</span><span style=""font-size: 7pt; color: rgb(34, 34, 34);"">\xa0\xa0</span><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">Both:</span></p><p class=""ql-indent-3""><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">3.1.1.</span><span style=""font-size: 7pt; color: rgb(34, 34, 34);"">\xa0</span><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">In patients who received first-line bortezomib, patient’s disease was not refractory to bortezomib (ie received &gt;6 months response to first-line bortezomib), nor were they intolerant to bortezomib; and</span></p><p class=""ql-indent-3""><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">3.1.2.</span><span style=""font-size: 7pt; color: rgb(34, 34, 34);"">\xa0</span><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">Daratumumab to be administered in combination with bortezomib and dexamethasone for weeks 1 through 24 and as a monotherapy from week 25 until disease progression; or</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">3.2.</span><span style=""font-size: 7pt; color: rgb(34, 34, 34);"">\xa0\xa0</span><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">Both:</span></p><p class=""ql-indent-3""><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">3.2.1.</span><span style=""font-size: 7pt; color: rgb(34, 34, 34);"">\xa0</span><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">In patients who received first-line bortezomib, patient’s disease was refractory to bortezomib in first line or they were intolerant to bortezomib; and</span></p><p class=""ql-indent-3""><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">3.2.2.</span><span style=""font-size: 7pt; color: rgb(34, 34, 34);"">\xa0</span><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">Daratumumab to be administered in combination with dexamethasone</span></p><p><b style=""font-size: 9pt; color: rgb(34, 34, 34);"">\xa0</b></p><p class=""ql-indent-1""><b style=""font-size: 9pt; color: rgb(34, 34, 34);"">Renewal</b><span style=""font-size: 9pt; color: rgb(34, 34, 34);""> - (relapsed/refractory multiple myeloma) only from a haematologist or any other medical practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">Both:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">1.</span><span style=""font-size: 7pt; color: rgb(34, 34, 34);"">\xa0\xa0</span><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">No evidence of disease progression; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">2.</span><span style=""font-size: 7pt; color: rgb(34, 34, 34);"">\xa0\xa0</span><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">The treatment remains appropriate and patient is benefitting from treatment.</span></p><p class=""ql-indent-1""><br></p><p>1.4<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee requested that its preferences for treatment of patients with multiple myeloma be reviewed should there be a change in the funding landscape regarding the first and/or second line treatment of multiple myeloma.</p>', 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': '<p>1.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that it had not previously considered the funding of daratumumab for patients with multiple myeloma in the third line setting. The Subcommittee considered that the data for the use of daratumumab after two prior lines comes from the CASTOR trial which compared the use of daratumumab in combination with bortezomib and dexamethasone (DBorD) versus bortezomib and dexamethasone (BorD) (<a href=""https://www.nejm.org/doi/full/10.1056/nejmoa1606038"" target=""_blank"">Palumbo A et al. N Engl J Med. 2016;375:754-66</a>). The Subcommittee noted that the efficacy (progression free survival) as demonstrated in the CASTOR trial of daratumumab beyond one prior line of treatment reduced from median time not reached at 30 months of follow up for patients with one prior line of treatment to approximately 9.8 months for patients with 2-3 prior lines of treatment (<a href=""https://pubmed.ncbi.nlm.nih.gov/30237264/"" target=""_blank"">Spencer et al. Haematologica.2018;103:2079-87</a>; <a href=""https://pubmed.ncbi.nlm.nih.gov/32482541/"" target=""_blank"">Mateos et al. Clin Lymphoma Myeloma Leuk. 2020. 20:509-518</a>). The Subcommittee noted that this indicates that daratumumab would be an efficacious treatment in this setting, although acknowledged that this efficacy is reduced compared to its use in earlier lines. The Subcommittee also noted that while carfilzomib would not be an option for all patients due to its toxicity profile, daratumumab would likely to be able meet the unmet need for this entire population. </p><p>1.2 <span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the use of daratumumab would be preferred in second line as it is more effective in this setting, represents a generally well tolerated regimen and that this is consistent with its use internationally. However, as daratumumab would be expected to provide similar benefit to other agents (pomalidomide and carfilzomib) that have been recommended for funding in later lines of therapy, the Subcommittee considered that its use in later lines could also address the health need for patients, if they were to progress on earlier lines of treatment.</p>', 'fs': '<p>1.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that it had not previously considered the funding of daratumumab for patients with multiple myeloma in the third line setting. The Subcommittee considered that the data for the use of daratumumab after two prior lines comes from the CASTOR trial which compared the use of daratumumab in combination with bortezomib and dexamethasone (DBorD) versus bortezomib and dexamethasone (BorD) (<a href=""https://www.nejm.org/doi/full/10.1056/nejmoa1606038"" target=""_blank"">Palumbo A et al. N Engl J Med. 2016;375:754-66</a>). The Subcommittee noted that the efficacy (progression free survival) as demonstrated in the CASTOR trial of daratumumab beyond one prior line of treatment reduced from median time not reached at 30 months of follow up for patients with one prior line of treatment to approximately 9.8 months for patients with 2-3 prior lines of treatment (<a href=""https://pubmed.ncbi.nlm.nih.gov/30237264/"" target=""_blank"">Spencer et al. Haematologica.2018;103:2079-87</a>; <a href=""https://pubmed.ncbi.nlm.nih.gov/32482541/"" target=""_blank"">Mateos et al. Clin Lymphoma Myeloma Leuk. 2020. 20:509-518</a>). The Subcommittee noted that this indicates that daratumumab would be an efficacious treatment in this setting, although acknowledged that this efficacy is reduced compared to its use in earlier lines. The Subcommittee also noted that while carfilzomib would not be an option for all patients due to its toxicity profile, daratumumab would likely to be able meet the unmet need for this entire population. </p><p>1.2 <span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the use of daratumumab would be preferred in second line as it is more effective in this setting, represents a generally well tolerated regimen and that this is consistent with its use internationally. However, as daratumumab would be expected to provide similar benefit to other agents (pomalidomide and carfilzomib) that have been recommended for funding in later lines of therapy, the Subcommittee considered that its use in later lines could also address the health need for patients, if they were to progress on earlier lines of treatment.</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Medium', 'fs': 'Medium', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2022', 'fs': 'Mar 2022', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cancer Treatments Advisory Committee at meeting Thursday 4 November 2021.', 'fs': 'Clinical advice received from Cancer Treatments Advisory Committee at meeting Thursday 4 November 2021.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Wfo1i2AB'}, 'Id': 'a0POZ00000Wfo1i2AB', 'Event_Date__c': '2022-03-11', 'Event_Description__c': 'Clinical advice received from Cancer Treatments Advisory Committee at meeting Thursday 4 November 2021.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Medium', 'Formatted_Date__c': 'Mar 2022', 'Published_Recommendation__c': '<p>1.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that daratumumab for the third-line treatment of relapsed or refractory multiple myeloma be listed with a <b>medium</b> <b>priority</b>, in the context of treatment of malignancy, subject to the following Special Authority criteria:</p><p class=""ql-indent-1""><b style=""font-size: 9pt; color: rgb(34, 34, 34);"">DARATUMUMAB</b></p><p class=""ql-indent-1""><b style=""font-size: 9pt; color: rgb(34, 34, 34);"">Initial application</b><span style=""font-size: 9pt; color: rgb(34, 34, 34);""> – (relapsed/refractory multiple myeloma) only from a haematologist or medical practitioner on the recommendation of a haematologist. Approvals valid for 12 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">All of the following:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">1.</span><span style=""font-size: 7pt; color: rgb(34, 34, 34);"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">Patient has relapsed or refractory multiple myeloma with progressive disease; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">2.</span><span style=""font-size: 7pt; color: rgb(34, 34, 34);"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">Patient has received two prior lines of treatment; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">3.</span><span style=""font-size: 7pt; color: rgb(34, 34, 34);"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">Either</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">3.1.</span><span style=""font-size: 7pt; color: rgb(34, 34, 34);"">\xa0\xa0</span><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">Both:</span></p><p class=""ql-indent-3""><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">3.1.1.</span><span style=""font-size: 7pt; color: rgb(34, 34, 34);"">\xa0</span><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">In patients who received first-line bortezomib, patient’s disease was not refractory to bortezomib (ie received &gt;6 months response to first-line bortezomib), nor were they intolerant to bortezomib; and</span></p><p class=""ql-indent-3""><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">3.1.2.</span><span style=""font-size: 7pt; color: rgb(34, 34, 34);"">\xa0</span><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">Daratumumab to be administered in combination with bortezomib and dexamethasone for weeks 1 through 24 and as a monotherapy from week 25 until disease progression; or</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">3.2.</span><span style=""font-size: 7pt; color: rgb(34, 34, 34);"">\xa0\xa0</span><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">Both:</span></p><p class=""ql-indent-3""><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">3.2.1.</span><span style=""font-size: 7pt; color: rgb(34, 34, 34);"">\xa0</span><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">In patients who received first-line bortezomib, patient’s disease was refractory to bortezomib in first line or they were intolerant to bortezomib; and</span></p><p class=""ql-indent-3""><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">3.2.2.</span><span style=""font-size: 7pt; color: rgb(34, 34, 34);"">\xa0</span><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">Daratumumab to be administered in combination with dexamethasone</span></p><p><b style=""font-size: 9pt; color: rgb(34, 34, 34);"">\xa0</b></p><p class=""ql-indent-1""><b style=""font-size: 9pt; color: rgb(34, 34, 34);"">Renewal</b><span style=""font-size: 9pt; color: rgb(34, 34, 34);""> - (relapsed/refractory multiple myeloma) only from a haematologist or any other medical practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">Both:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">1.</span><span style=""font-size: 7pt; color: rgb(34, 34, 34);"">\xa0\xa0</span><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">No evidence of disease progression; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">2.</span><span style=""font-size: 7pt; color: rgb(34, 34, 34);"">\xa0\xa0</span><span style=""font-size: 9pt; color: rgb(34, 34, 34);"">The treatment remains appropriate and patient is benefitting from treatment.</span></p><p class=""ql-indent-1""><br></p><p>1.4<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee requested that its preferences for treatment of patients with multiple myeloma be reviewed should there be a change in the funding landscape regarding the first and/or second line treatment of multiple myeloma.</p>', 'Published_Application__c': '<p>1.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that it had not previously considered the funding of daratumumab for patients with multiple myeloma in the third line setting. The Subcommittee considered that the data for the use of daratumumab after two prior lines comes from the CASTOR trial which compared the use of daratumumab in combination with bortezomib and dexamethasone (DBorD) versus bortezomib and dexamethasone (BorD) (<a href=""https://www.nejm.org/doi/full/10.1056/nejmoa1606038"" target=""_blank"">Palumbo A et al. N Engl J Med. 2016;375:754-66</a>). The Subcommittee noted that the efficacy (progression free survival) as demonstrated in the CASTOR trial of daratumumab beyond one prior line of treatment reduced from median time not reached at 30 months of follow up for patients with one prior line of treatment to approximately 9.8 months for patients with 2-3 prior lines of treatment (<a href=""https://pubmed.ncbi.nlm.nih.gov/30237264/"" target=""_blank"">Spencer et al. Haematologica.2018;103:2079-87</a>; <a href=""https://pubmed.ncbi.nlm.nih.gov/32482541/"" target=""_blank"">Mateos et al. Clin Lymphoma Myeloma Leuk. 2020. 20:509-518</a>). The Subcommittee noted that this indicates that daratumumab would be an efficacious treatment in this setting, although acknowledged that this efficacy is reduced compared to its use in earlier lines. The Subcommittee also noted that while carfilzomib would not be an option for all patients due to its toxicity profile, daratumumab would likely to be able meet the unmet need for this entire population. </p><p>1.2 <span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the use of daratumumab would be preferred in second line as it is more effective in this setting, represents a generally well tolerated regimen and that this is consistent with its use internationally. However, as daratumumab would be expected to provide similar benefit to other agents (pomalidomide and carfilzomib) that have been recommended for funding in later lines of therapy, the Subcommittee considered that its use in later lines could also address the health need for patients, if they were to progress on earlier lines of treatment.</p>', 'Status_History__c': 'a132P000000DbnJQAS'}, 'change': None}]",Aug 2021,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2022', 'fs': 'Mar 2022', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Wfo1g2AB'}, 'Id': 'a0POZ00000Wfo1g2AB', 'Event_Date__c': '2022-03-01', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Mar 2022', 'Status_History__c': 'a132P000000ECg9QAG'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2022', 'fs': 'Mar 2022', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Wfo1h2AB'}, 'Id': 'a0POZ00000Wfo1h2AB', 'Event_Date__c': '2022-03-01', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Mar 2022', 'Status_History__c': 'a132P000000ECgEQAW'}, 'change': None}]",Mar 2022,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,,,False,False
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,,,False,False
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,,,False,False
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,,,False,False
